Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043330 | 0.94 | LCK (0.59) | LCKSRC | |
| SCHEMBL4038739 | 0.86 | LCK (0.56) | LCKSRC | |
| SCHEMBL4041863 | 0.85 | LCK (0.51) | LCKSRC | |
| SCHEMBL4036355 | 0.85 | LCK (0.51) | LCKSRC | |
| SCHEMBL4036251 | 0.85 | LCK (0.51) | LCKSRC | |
| SCHEMBL4036241 | 0.81 | LCK (0.51) | LCKSRC | |
| SCHEMBL4038784 | 0.81 | LCK (0.51) | LCKSRC | |
| SCHEMBL4036352 | 0.81 | LCK (0.51) | LCKSRC | |
| SCHEMBL4038056 | 0.80 | LCK (0.56) | LCKSRC | |
| SCHEMBL4039834 | 0.80 | LCK (0.56) | LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1066286-A4 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | claimed |
| EP-1066286-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999045009-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-10 | — | — | WO | claimed |
| WO-2009109504-A1 | ENOL CARBAMATE DERIVATIVES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1483273-B1 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | BERENS ULRICH | 2006-10-26 | — | — | US | disclosed |
| US-7094907-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20040260091-A1 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-5565593-A | FERROCENYL-1,1'-BIS(DIETHYPHOSPHONITE); CHEMICAL INTERMEDIATES FOR PREPERATION OF PHOSPHOLANE LIGANDS AND CHIRAL COMPLEXES, USEFUL AS CATALYSTS FOR CARRYING OUT ENANTIOSELECTIVE REACTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5559267-A | ENANTIOMORPHS, STEREOCHEMICAL CONTROL AND ASSYMETRIC INDUCTION, HYDROGENATION OF UNSATURATED ESTERS, COORDINATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| US-5532395-A | HYDROGENATION CATALYSTS ) | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5386061-A | Reacting a bis(primary phosphine in the presence of a strong base with a cyclic sulfate; cyclization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| US-5329015-A | Catalysts for stereospecific reactions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0592552-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES. | DU PONT (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993001199-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5171892-A | Chiral phospholanes via chiral 1,4-diol cyclic sulfates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | NR2E3, WNK2, OXSR1 | LCK 377/4885SRC 573/4885 |
| US-20040260091-A1 | Ligands for asymmetric reactions | COASY, ICMT, AP2M1 | LCK 566/4885SRC 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.